Mohammad Pasha

Interleukin-6 signaling pathway in targeted therapy for cancer

New treatment for acute myelogenous leukemia

Synthesis of C8N9 Annulated Purines by Iron‐Catalyzed CH Amination

The JAK/STAT signaling pathway: from bench to clinic

Targeting apoptosis in cancer therapy

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Iron Catalysis in Organic Synthesis

Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery

A Review on State-of-the-Art Power Line Inspection Techniques

Acute Myeloid Leukemia

Targeting the JAK/STAT pathway in solid tumors

Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?

Detectability of Degraded Joint Discontinuities in HV Power Lines Through TDR-Like Remote Monitoring

An Alternative Method for Locating Faults in Transmission Line Networks Based on Time Reversal

2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1

Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Real-Time Overhead Transmission-Line Monitoring for Dynamic Rating